Pro Bono Bio TM is a new international pharmaceutical company that launched today. Pro Bono Bio is the result of a three year Anglo/Russian project, developed by Celtic Pharma Holdings in London. Pro ...

Pro Bono Bio Announces the Successful Development of Subcutaneous and Long-Acting Blood Factors VIIa,VIII and IX for the Treatment of Haemophilia Subcutaneous blood factors expected to revolutionise ...

Pro Bono Bio™ is pleased to announce that its innovative product FLEXISEQ, a new nanotechnology based treatment for osteoarthritis, has received approval for sale in Malaysia. This follows the ...

LONDON – A new Anglo-Russian biopharmaceutical company has been formed with $300 million from the Russian government, matched by a further $300 million from investors in the London-based private ...

Chaz Salvatore Bono (born Chastity Sun Bono on March 4, 1969) is the only child of late singer/congressman Sonny Bono and singer/actress Cher. Chaz Bono is currently 57 years old. Like many children ...

LONDON (Reuters) - The Russian government has become the leading shareholder in a new Anglo-Russian drug company with an unusual mission to develop nanotechnology, help the world's poor -- and list in ...

> Pro Bono Bio has completed its first series of trials of subcutaneous treatments for hemophilia, showing that the therapies improve blood clotting for extended periods. These would make ...